Edward B. Garon
爱德华·加伦
MD, MS
Professor of Medicine; Director of Thoracic Oncology Research医学教授；胸部肿瘤研究主任
👥Biography 个人简介
Dr. Edward Garon is best known as the principal investigator of KEYNOTE-001, the landmark trial that defined pembrolizumab's role in NSCLC and established PD-L1 as a predictive biomarker. His work catalyzed the immunotherapy revolution in lung cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KEYNOTE-001 Principal Investigator
Led KEYNOTE-001, the pivotal phase I/II study that established pembrolizumab efficacy in NSCLC and demonstrated PD-L1 TPS ≥50% as a biomarker, directly leading to first-line FDA approval.
PD-L1 as Predictive Biomarker
Developed and validated the PD-L1 tumor proportion score threshold for patient selection in first-line pembrolizumab monotherapy, enabling a biomarker-driven immunotherapy strategy for NSCLC.
Novel Immunotherapy Combinations
Leads clinical trials investigating pembrolizumab combinations with targeted agents and novel immunomodulators, working to extend immunotherapy benefit to PD-L1-low and driver-mutant NSCLC populations.
Representative Works 代表性著作
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer (KEYNOTE-001)
New England Journal of Medicine (2015)
Landmark trial establishing pembrolizumab activity in NSCLC and identifying PD-L1 ≥50% as a clinically validated predictive threshold, reshaping first-line lung cancer treatment.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (KEYNOTE-024)
New England Journal of Medicine (2016)
Demonstrated pembrolizumab superiority over chemotherapy in PD-L1-high NSCLC, establishing a new first-line standard of care for this patient population.
Five-Year Overall Survival for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab
Journal of Clinical Oncology (2019)
Reported durable long-term survival with pembrolizumab, confirming the curative potential of checkpoint inhibition in a subset of NSCLC patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Lecia V. Sequist
Massachusetts General Hospital / Harvard Medical School
Mark G. Kris
Memorial Sloan Kettering Cancer Center
Geoffrey R. Oxnard
Foundation Medicine / Harvard Medical School
Alice T. Shaw
Novartis Institutes for BioMedical Research / Massachusetts General Hospital
关注 爱德华·加伦 的研究动态
Follow Edward B. Garon's research updates
留下邮箱，当我们发布与 Edward B. Garon（UCLA Health / David Geffen School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment